Actively Recruiting
Extended Effects of Cannabis Abstinence on Clinical Symptoms and Cognition in Depression
Led by Centre for Addiction and Mental Health · Updated on 2025-02-24
52
Participants Needed
1
Research Sites
318 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The prevalence of major depressive disorder (MDD) is \~5.0%, and rates of co-occurring SUDs in these patients approach 40-50%. Specifically, rates of co-morbid cannabis use disorder (CUD) in patients with MDD are elevated 2-3 fold compared to 2.9% in the general population, and is associated with poorer treatment outcomes and impaired cognitive and psychosocial functioning in comparison to MDD patients without CUD. Most studies of cannabis use in MDD are cross-sectional in design, and therefore causal relationships are unclear. This study investigates the effects of cannabis abstinence over a 28-day period in patients with MDD with co-occurring CUD using a randomized controlled design, namely contingent reinforcement.
CONDITIONS
Official Title
Extended Effects of Cannabis Abstinence on Clinical Symptoms and Cognition in Depression
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 55 years
- Diagnosis of moderate to severe cannabis use disorder by DSM-5 criteria
- Diagnosis of major depressive disorder by DSM-5 criteria
- Stable outpatient on antidepressant medication for at least three months
- Hamilton Depression Rating Scale score between 12 and 25 at baseline
- Full-Scale IQ of 80 or higher
- Non-treatment seeking cannabis user
- Sufficient motivation and effort shown by a Test of Memory Malingering score of 45 or higher
You will not qualify if you...
- Substance use disorder for alcohol or other illicit drugs (except cannabis, nicotine, caffeine) in past 6 months
- Positive urine test for illicit substances other than cannabis, nicotine, or caffeine
- Current suicidal or homicidal thoughts
- Diagnosis of psychotic disorder
- Currently seeking treatment for cannabis use
- Diagnosis of bipolar disorder
- Head injury with loss of consciousness longer than 5 minutes
- Hamilton Depression Rating Scale score outside 12-25 range
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Centre for Addiction and Mental Health
Toronto, Ontario, Canada, M5T 1R8
Actively Recruiting
Research Team
M
Maryam Sorkhou, HBSc
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here